Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth

ErbB3, a member of the ErbB family of receptor tyrosine kinases, is a potent activator of phosphatidyl inositol-3 kinase (PI3K) and mTOR signaling, driving tumor cell survival and therapeutic resistance in breast cancers. In luminal breast cancers, ErbB3 upregulation following treatment with the ant...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncogene
Autors principals: Morrison, Meghan M., Williams, Michelle M., Vaught, David B., Hicks, Donna, Lim, Jiyeon, McKernan, Courtney, Aurisicchio, Luigi, Cennaro, Gilberto, Simion, Catalina, Sweeney, Colleen, Cook, Rebecca S.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4703573/
https://ncbi.nlm.nih.gov/pubmed/26148232
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2015.169
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars